Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).

MLA

Wagner, Uwe, et al. “Gefitinib in Combination with Tamoxifen in Patients with Ovarian Cancer Refractory or Resistant to Platinum-Taxane Based Therapy--a Phase II Trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).” Gynecologic Oncology, vol. 105, no. 1, Apr. 2007, pp. 132–37. EBSCOhost, https://doi.org/10.1016/j.ygyno.2006.10.053.

APA

Wagner, U., du Bois, A., Pfisterer, J., Huober, J., Loibl, S., Lück, H.-J., Sehouli, J., Gropp, M., Stähle, A., Schmalfeldt, B., Meier, W., & Jackisch, C. (2007). Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecologic Oncology, 105(1), 132–137. https://doi.org/10.1016/j.ygyno.2006.10.053

Chicago

Wagner, Uwe, Andreas du Bois, Jacobus Pfisterer, Jens Huober, Sybille Loibl, Hans-Joachim Lück, Jalid Sehouli, et al. 2007. “Gefitinib in Combination with Tamoxifen in Patients with Ovarian Cancer Refractory or Resistant to Platinum-Taxane Based Therapy--a Phase II Trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).” Gynecologic Oncology 105 (1): 132–37. doi:10.1016/j.ygyno.2006.10.053.